ÀÓ»ó °Ëü °Ë»ç¿¡¼ ÃàÀûµÈ ³ëÇϿ츦 ¹ÙÅÁÀ¸·Î
´Ù¾çÇÑ ¿¬±¸ºÐ¾ß¿¡ ÁýÁßÇÏ°í ÀÖ½À´Ï´Ù.
dzºÎÇÑ ÀÇ·á±â±â ÀÓ»ó½ÃÇè ¼öÇà ³ëÇÏ¿ì º¸À¯
´Ü°èº° ÃÖÀûÈ Áö¿ø
±¹³» ÃÖ´ë ¼öŹ±â°üÀ¸·Î ´Ù¾çÇÑ °Ëü º¸À¯
´Ù¾çÇÑ ÀÓ»ó ½ÃÇè °¡´É
ÀÓ»óÀû ¼º´É Æò°¡ ¹× À¯È¿¼º °Ë»ç±îÁö One site
½Å¼ÓÇÑ ÀÓ»ó ½ÃÇè °¡´É
ÀÎü¿¡¼ À¯·¡ÇÑ ½Ã·á¸¦ °Ëü·Î ÇÏ¿© °Ëü ÁßÀÇ ¹°ÁúÀ» °Ë»çÇÏ¿© Áúº´ Áø´Ü,
¿¹ÈÄ °üÂû, Ç÷¾× ¶Ç´Â Á¶Á÷ ÀûÇÕ¼º ÆÇ´Ü µîÀÇ Á¤º¸ Á¦°øÀ» ¸ñÀûÀ¸·Î ü¿Ü¿¡¼
»ç¿ëµÇ´Â ½Ã¾àÀ» ÅëĪÇÕ´Ï´Ù. ´Ù¸¸, ½ÇÇè½Ç¿¡¼ Á¶Á¦ÇÏ¿© »ç¿ëÇÏ´Â
Á¶Á¦½Ã¾àÀº Á¦¿ÜµË´Ï´Ù.
ÀÇ·á±â±â¹ý Á¦6Á¶Á¦2Ç×(Á¦Á¶¾÷ÀÇ Çã°¡ µî) ¹× Á¦15Á¶Á¦2Ç×(¼öÀÔ¾÷ÀÇ Çã°¡
µî)¿¡ µû¶ó Á¦Á¶(¼öÀÔ)ÀÚ´Â Á¦Á¶ ¶Ç´Â ¼öÀÔÇÏ·Á´Â ÀÇ·á±â±â¿¡ ´ëÇÏ¿© Çã°¡,
½Å°í, ÀÎÁõ ¹Þ¾Æ¾ßÇϸç, ´ë»óÀº ´ÙÀ½°ú °°½À´Ï´Ù.
µî±Þ | ü¿ÜÁø´Ü¿ë ÀÇ·á±â±â ºÐ·ù±âÁØ |
---|---|
1µî±Þ | °³Àΰú °øÁߺ¸°Ç¿¡ ¹ÌÄ¡´Â ÀáÀçÀû À§ÇؼºÀÌ ³·Àº °æ¿ì |
2µî±Þ | °³Àο¡°Ô ÁßÁõµµÀÇ ÀáÀçÀû À§ÇؼºÀ» °¡Áö¸ç °øÁߺ¸°Ç¿¡ ¹ÌÄ¡´Â ÀáÀçÀû À§ÇؼºÀÌ ³·Àº °æ¿ì |
3µî±Þ | °³Àο¡°Ô °íµµÀÇ ÀáÀçÀû À§ÇؼºÀ» °¡Áö¸ç °øÁߺ¸°ÇÀÇ ÁßÁõµµÀÇ ÀáÀçÀû À§ÇؼºÀ» °¡Áö´Â °æ¿ì |
4µî±Þ | °³Àΰú °øÁߺ¸°Ç¿¡ °íµµÀÇ À§ÇؼºÀ» °¡Áö´Â °æ¿ì |
Æ¯ÈµÈ ±â¼ú°³¹ß Áö¿ø½Ã½ºÅÛÀ» ÅëÇÏ¿© °³¹ß ¾ÆÀ̵ð¾î¿¡¼ºÎÅÍ
ü¿ÜÁø´Ü¿ë ÀÇ·á±â±â Æò°¡ µµÃâ±îÁö ½Å¼Ó¢«Á¤È®ÇÑ °á°ú Á¦°øÀÌ °¡´ÉÇÕ´Ï´Ù.
ÀÇ·á±â±â ÇØ´ç¿©ºÎ È®ÀÎ
ÀÇ·á±â±â¿¡ ÇØ´çÇÏ´Â °æ¿ì
µî±Þ¿¡ °üÇÑ ±ÔÁ¤¿¡
µû¶ó 1,2,3,4 µî±ÞÀ¸·Î ºÐ·ù
[½Å°í]
[ÀÎÁõ,Çã°¡]
[Çã°¡]
NO | ¿µ¹® | ±¹¹® | NO | ¿µ¹® | ±¹¹® |
---|---|---|---|---|---|
1 | Adverse Event | ÀÌ»ó¹ÝÀÀ | 17 | Informed Consent Form | ½ÃÇè´ë»óÀÚ¼³¸í¼ |
2 | Applicable Regulatory Requirement | °ü·Ã ±ÔÁ¤ | 18 | Inspection | ½ÇÅÂÁ¶»ç |
3 | Audit | Á¡°Ë | 19 | Institution | ÀÓ»ó½ÃÇè½Ç½Ã±â°ü |
4 | Audit Certificate | Á¡°ËÈ®Àμ | 20 | Institutional Review Board | ÀÓ»ó½ÃÇè½É»çÀ§¿øȸ |
5 | Case Report Form | Áõ·Ê±â·Ï¼ | 21 | Investigator | ½ÃÇèÀÚ |
6 | Clinical Trial/Study | ÀÓ»ó½ÃÇè | 22 | Monitor | ÀÓ»ó½ÃÇè¸ð´ÏÅÍ¿ä¿ø |
7 | Clinical Trial/Study Report | ÀÓ»ó½ÃÇè °á°úº¸°í¼ | 23 | Multicenter trial | ´Ù±â°üÀÓ»ó½ÃÇè |
8 | Comparator | ´ëÁ¶±â±â | 24 | Nonclinical Study | ºñÀÓ»ó½ÃÇè |
9 | Comparator | ´ëÁ¶¾à | 25 | Principal Investigator | ½ÃÇèÃ¥ÀÓÀÚ |
10 | Compliance | ÀÓ»ó½ÃÇèÀÇ Áؼö | 26 | Protocol | ÀÓ»ó½ÃÇè°èȹ¼ |
11 | Confidentiality | ºñ¹Ðº¸Àå | 27 | Protocol Amendment | ÀÓ»ó½ÃÇè º¯°æ°èȹ¼ |
12 | Contract | ÀÓ»ó½ÃÇè°è¾à¼ | 28 | Site Management Organization | ÀÓ»ó½ÃÇè½Ç½Ã Áö¿ø±â°ü |
13 | Contract Research Organization | ÀÓ»ó½ÃÇè¼öŹ±â°ü | 29 | Source Document | ±Ù°Å¹®¼ |
14 | Coordinating Committee | Á¶Á¤À§¿øȸ | 30 | Standard Operating Procedure | Ç¥ÁØÀÛ¾÷Áöħ¼ |
15 | Essential Document | ÀÓ»ó½ÃÇè ±âº»¹®¼ | 31 | Subject/Trial Subject | ÀÓ»ó½ÃÇè´ë»óÀÚ |
16 | Informed Consent | ´ë»óÀÚµ¿ÀÇ | 32 | Subject/Trial Subject | ÀÓ»ó½ÃÇèÇÇÇèÀÚ |